<DOC>
	<DOCNO>NCT02403895</DOCNO>
	<brief_summary>Open -- label , phase 2a , multi-centre , single-arm study ass efficacy safety AZD2014 weekly paclitaxel patient squamous non-small cell lung cancer ( NSCLC )</brief_summary>
	<brief_title>AZD2014 Weekly Paclitaxel Squamous NSCLC</brief_title>
	<detailed_description>This open-label , phase 2a , multi-centre , single-arm study ass efficacy safety combination AZD2014 weekly paclitaxel patient squamous non-small cell lung cancer ( NSCLC ) relapse refractory conventional treatment least 1 prior treatment standard care ( SOC ) weekly paclitaxel treatment appropriate treatment choice . The study simultaneously enrol patient follow two group . Group A ( intensive PK ) enrol 10 evaluable patient intra-patient evaluation impact paclitaxel exposure AZD2014 , impact AZD2014 exposure paclitaxel via intensive PK sample non-compartmental PK analysis technique ( NCA ) . Group B ( sparse PK ) enrol 30 patient sparse sample population PK model technique employ estimate exposure AZD2014 administer combination weekly paclitaxel dose regimen . The efficacy safety AZD2014 weekly paclitaxel combination evaluate 40 patient use RECIST 1.1 , observation AEs/SAEs use conventional safety parameter . Eligible patient receive study treatment consist single weekly paclitaxel infusion ( 80 mg/m2 ) Day 1 week twice daily ( BD ) 50 mg dos AZD2014 first 3 day week 6 week [ except Group A patient Week 1 Cycle 1 take 50 mg BD dose AZD2014 Days 3 , 4 5 ( Days 4 , 5 6 ) accommodate PK sample ] , follow break treatment paclitaxel AZD2014 give . This 7-week schedule compose one cycle treatment . AZD2014 administer oral tablet fast patient ( i.e. , food 2 hour 1 hour dose ) . Patients receive 6 cycle paclitaxel , although additional cycle paclitaxel may give deem appropriate Investigator .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically proven squamous nonsmall cell lung cancer ( NSCLC ) treatment weekly paclitaxel appropriate treatment option . 2 . Relapsed refractory disease least one line prior therapy . Subjects must previously receive appropriate line ( ) standard care ( SOC ) treatment . 3 . Measurable disease RECIST v1.1 criterion 4 . Life expectancy least 12 week . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 1 . Radiotherapy ( except palliative reason ) , chemotherapy , endocrine therapy , immunotherapy previous 3 week ( 4 week investigational medicinal product 6 week nitrosoureas MitomycinC ) treatment . 2 . Ongoing toxic manifestation previous treatment . Exceptions alopecia Grade 1 toxicity , opinion Investigator , exclude patient . 3 . Known leptomeningeal involvement , brain metastasis spinal cord compression . 4 . History hypersensitivity ( &gt; Grade 2 ) active inactive excipients AZD2014 , drug contain Cremophor , taxanes structurally/chemically similar drug 5 . Current refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption AZD2014 6 . Patients Diabetes Type I uncontrolled Type II ( HbA1c &gt; 59 mmol/mol assess locally ) judge Investigator 7 . Major surgery within 4 week prior entry study ( exclude placement vascular access ) , minor surgery within 2 week entry study patient yet recover 8 . Adequate hematologic function independent transfusion growth factor support least 7 day prior screen ( exception pegylated GCSF ( pegfilgrastim ) darbepoetin require least 14 day prior screen ) , define : Absolute neutrophil count 1500 cells/mm3 ( 1.5 x 109/L ) Platelet count 100.000 cells/mm3 ( 100 x 109/L ) Haemoglobin 9.0 g/dL 9 . Adequate hepatic renal function define : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) 2.5 x upper limit normal ( ULN ) demonstrable liver metastases 5 x ULN presence liver metastases Alkaline phosphatase ( ALP ) &lt; 5 x ULN Serum bilirubin 1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin ) Estimated Creatinine Clearance 50 ml/min ( CockcroftGault ) serum creatinine 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>